ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO582

Polymorphism in the Human Matrix Gla Protein Gene Is Associated with the Progression of Osteoporosis in Hemodialysis Patients

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Hasuike, Yukiko, Internal Medicine, Division of Kidney and Dialysis, Nishinomiya, Japan
  • Kimura, Tomoko, Internal Medicine, Division of Kidney and Dialysis, Nishinomiya, Japan
  • Mizusaki, Kosuke, Internal Medicine, Division of Kidney and Dialysis, Nishinomiya, Japan
  • Kida, Aritoshi, Internal Medicine, Division of Kidney and Dialysis, Nishinomiya, Japan
  • Nanami, Masayoshi, Internal Medicine, Division of Kidney and Dialysis, Nishinomiya, Japan
  • Nagasawa, Yasuyuki, Internal Medicine, Division of Kidney and Dialysis, Nishinomiya, Japan
  • Kuragano, Takahiro, Internal Medicine, Division of Kidney and Dialysis, Nishinomiya, Japan
  • Ishihara, Masaharu, Internal Medicine, Division of Kidney and Dialysis, Nishinomiya, Japan
Background

Matrix Gla protein (MGP) is an important protein related osteoporosis and vascular calcification. Single nucleotide polymorphisms (SNPs) coding regions of the MGP gene affect the transcriptional activity. We investigated the relationship between the SNPs and progression of osteoporosis and vascular calcification in patients undergoing hemodialysis (HD).

Methods

This is a prospective and single center study. Using blood samples, SNPs on the MGP gene promoter T-138C (rs1800802, direct sequencing) was investigated. Bone mineral density (femoral, DEXA, T score) and vascular calcification index (ACI, abdominal CT) were examined at start and 1-year after. Several factors related bone: fibroblast growth hormone, bone-type alkaline phosphatase (BAP), and tartrate-resistant acid phosphatase (TRACP5b), uremia: Ca, P, parathyroid hormone-intact, and 25(OH) vitamin D, and inflammation: high-sensitivity CRP, tumor necrosis factor-α, interleukin-6 were measured. The change of T score and ACI were investigated.

Results

The distribution of the T-138C genotype was TT (47.5%), CT (40.0%) and CC (12.5%,). T score of all participants (n=80) at 1-year after was lower than that at start. T score for the CT and CC genotype were significantly decreased. The changes of T scores for the CC, CT, and TT genotype were shown (Figure 1a). The multiple regression analyses revealed that the change of BAP, TRACP-5b, and ACI were the independent predictors of T score change (standardized regression coefficients were -0.443, -0.276, and 0.400, respectively, R2=0.659). ACI for each genotype were increased (Figure 1b), and there were no differences of ACI change among 3 genotypes.

Conclusion

The MGP-138C genotype may be associated with decrease in T scores in HD patients. The genotype of the MGP gene might be a genomic biomarker that is predictive of osteoporosis.